Nodality

Nodality was a South San Francisco biotechnology company that developed Single Cell Network Profiling (SCNP), a diagnostic platform measuring signalling responses in individual cells to predict which patients would respond to a given cancer or autoimmune therapy. Built on Garry Nolan's Stanford work, it sold its PathPro assay panels and ran drug-development collaborations with Pfizer, UCB and Johnson & Johnson. Its last public activity dates to 2015 and its website no longer resolves.